Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
29 juin 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
22 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 patients in EU ...